Navigation Links
Device drops blood pressure in patients with difficult-to-treat hypertension
Date:4/5/2011

A device designed to treat people with resistant hypertension helped lower blood pressure by 33 points, a substantial drop that would otherwise require patients to take an additional three or four drugs, on top of this subgroup's usual regimen of up to five drugs, to control their difficult-to-treat condition.

The device, called the Rheos System, was tested in a pivotal Phase III study presented today as a late-breaking clinical trial at the American College of Cardiology's Annual Scientific Sessions. It is the first device to be tested in a large-scale clinical trial for the treatment of hypertension and works by activating the body's natural blood flow regulation mechanism to reduce high blood pressure.

Though the therapy led to a considerable drop in blood pressure and had a good safety profile, it did not meet all of the study goals. Another, more focused trial testing the device is needed before the U.S. Food and Drug Administration will consider approving the treatment, according to physicians who led the study.

"The device works extremely well and there is a large group of patients who would benefit from this therapy, but we need to go back and identify this group more clearly," said John Bisognano, M.D., Ph.D., a lead study investigator from the University of Rochester Medical Center. "This outcome is not uncommon. While the initial results are not as crisp as we would expect, it is clear from looking at the data that there are therapeutic benefits to pursue."

The pivotal trial included 265 patients with resistant hypertension treated at 40 medical centers in the United States and two in Europe, and is the latest in a series of studies that have shown the device is beneficial.

People who do not respond to the typical treatment regimen for high blood pressure, which includes one to three medications, coupled with improved nutrition and exercise, have resistant hypertension. These patients are at a far greater risk for stroke, heart attack, heart failure, kidney disease and death, which is why new therapies like Rheos are needed.

"Current drugs and lifestyle modifications can only do so much. I treat a huge number of people who are doing everything right taking their medications, maintaining a healthy diet, working out and they still develop resistant hypertension," noted Bisognano, Professor of Medicine and Director of Outpatient Cardiology at the Medical Center.

The prevalence of resistant hypertension is unknown, but current estimates suggest that between 10 and 15 percent of people with high blood pressure are in the truly resistant group. Many people with a family history of high blood pressure have the condition. Older age is also associated with the disorder.

The Rheos System, developed by CVRx Inc. of Minneapolis, regulates blood pressure much like a pacemaker regulates heart rhythm. A battery-powered implantable generator is inserted under the skin near the collarbone and two leads, or wires, run from the generator to the carotid arteries, the two main arteries that supply blood to the head. The device triggers specific receptors on these arteries, known as carotid baroreceptors key regulators of blood flow in the body.

These receptors then send signals that are interpreted by the brain as a rise in blood pressure. The body responds to this phantom rise in blood pressure by taking action to lower it, including relaxing the blood vessels and reducing the heart rate.

Rheos was first implanted in the United States in 2005 by physicians at the University of Rochester Medical Center. According to Bisognano, the next trial will include a different selection of patients and use a slightly different implantation technique. He believes the study will likely show that the device, in combination with drug therapy and lifestyle changes, provides major benefit for people with resistant hypertension.

In a separate sub-analysis from the pivotal Phase III study, researchers found that the Rheos device also leads to positive changes in the structure and function of the heart. Years of high blood pressure can damage the heart, resulting in the thickening and enlargement of the heart. Rheos reversed this damage in patients, improving the overall pumping action of the heart an outcome that doesn't always result from drug therapy.

"The device lowers blood pressure in a way that actually benefits patients beyond changing their numbers it improves the structure of the heart which in turn improves overall cardiac function," said Bisognano.


'/>"/>

Contact: Emily Boynton
emily_boynton@urmc.rochester.edu
585-273-1757
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. Embedded Mobile & M2M Device revenues to Rise to Almost $19 Billion Globally by 2014, Says Juniper Research
2. Scott & White Memorial Hospital uses device to revolutionize treatment of traumatic aortic injury
3. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
4. Device Helps Kids With Single-Sided Deafness
5. Apex Heart Care, First Arizona Clinic to Install Shape-HF; New Medical Device Measures Patient Physiology to Define Shortness of Breath
6. Innovative Medical Alert Device Sets a New Standard in PERS Industry
7. Aurora BayCare Hosts Statewide Medical Device Business Development Meeting
8. EPIC study finds new embolic protection device had 97.5 percent success rate during carotid artery stenting
9. Santa Rosa Consulting Announces New Free Education Series: Hot Topics in Patient Care Device Integration
10. SDI Reports: Nearly a Third Of Physicians Use Handheld and Smartphone Devices to Access Medical Information - Physicians Most Likely to be Using Apple iPhone
11. Power Plate Unveils the First Cable-Based Upper-Body Vibration Training Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , ... May 26, 2016 , ... ... to oncology professionals, has added National Cancer Institute-designated University of Virginia (UVA) ... In this new partnership, OncLive’s editorial and marketing teams will publicize and promote ...
(Date:5/26/2016)... ... May 26, 2016 , ... A health conscious snack that ... Dough Bar, has ignited an undeniable buzz in the protein product community by ... just any doughnut.  These doughnuts are packed with 11 grams of protein and made ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... provide strategic sales leadership and to further develop their rapidly expanding portfolio of ... Business Administration with a concentration in Marketing and an M.B.A. with concentration in ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... efforts for several years, and the efforts have paid off. Since implementation ... new standards of care to enhance perioperative patient experiences and reduce costly complications. ...
(Date:5/26/2016)... ... , ... Dr. LeRoy Perry’s recently authored whitepaper, “Tech Neck and ROI (return ... of users, hundreds of millions of whom are coming into the workplace with pain ... common action of looking down at hand-held technology devices (tablets, smartphones) for extended periods ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 26, 2016 A key trend ... the emergence of new treatments. Cardax, a development stage ... treatment. The therapy is expected to fulfil large unmet ... is conducting studies to develop new treatments for osteoarthritis. ... genes involved in osteoarthritis are being investigated, and early ...
(Date:5/26/2016)... , May 26, 2016   Change ... and analytics, network solutions and technology-enabled services ... it entered into a strategic channel partnership ... outpatient software solutions and revenue cycle management ... hospitals and rehabilitation clinics to optimize revenue, ...
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
Breaking Medicine Technology: